These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26868617)

  • 1. Database Extraction of Metabolite Information of Drug Candidates: Analysis of 27 AstraZeneca Compounds with Human Absorption, Distribution, Metabolism, and Excretion Data.
    Iegre J; Hayes MA; Thompson RA; Weidolf L; Isin EM
    Drug Metab Dispos; 2016 May; 44(5):732-40. PubMed ID: 26868617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of a Micropatterned Cocultured Hepatocyte System To Predict Preclinical and Human-Specific Drug Metabolism.
    Ballard TE; Wang S; Cox LM; Moen MA; Krzyzewski S; Ukairo O; Obach RS
    Drug Metab Dispos; 2016 Feb; 44(2):172-9. PubMed ID: 26608083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites.
    Dalvie D; Obach RS; Kang P; Prakash C; Loi CM; Hurst S; Nedderman A; Goulet L; Smith E; Bu HZ; Smith DA
    Chem Res Toxicol; 2009 Feb; 22(2):357-68. PubMed ID: 19146377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Method for rapid metabolite profiling of drug candidates in fresh hepatocytes using liquid chromatography coupled with a hybrid quadrupole linear ion trap.
    Gao H; Materne OL; Howe DL; Brummel CL
    Rapid Commun Mass Spectrom; 2007; 21(22):3683-93. PubMed ID: 17937450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of radiolabeled compounds in drug metabolism and pharmacokinetic studies.
    Isin EM; Elmore CS; Nilsson GN; Thompson RA; Weidolf L
    Chem Res Toxicol; 2012 Mar; 25(3):532-42. PubMed ID: 22372867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From known knowns to known unknowns: predicting in vivo drug metabolites.
    Pelkonen O; Tolonen A; Korjamo T; Turpeinen M; Raunio H
    Bioanalysis; 2009 May; 1(2):393-414. PubMed ID: 21083174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug metabolites as cytochrome p450 inhibitors: a retrospective analysis and proposed algorithm for evaluation of the pharmacokinetic interaction potential of metabolites in drug discovery and development.
    Callegari E; Kalgutkar AS; Leung L; Obach RS; Plowchalk DR; Tse S
    Drug Metab Dispos; 2013 Dec; 41(12):2047-55. PubMed ID: 23792812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
    Zhang D; He K; Raghavan N; Wang L; Mitroka J; Maxwell BD; Knabb RM; Frost C; Schuster A; Hao F; Gu Z; Humphreys WG; Grossman SJ
    Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of quantitative NMR in pharmacological evaluation of biologically generated metabolites: implications in drug discovery.
    Mutlib A; Espina R; Vishwanathan K; Babalola K; Chen Z; Dehnhardt C; Venkatesan A; Mansour T; Chaudhary I; Talaat R; Scatina J
    Drug Metab Dispos; 2011 Jan; 39(1):106-16. PubMed ID: 20952552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fractional mass filtering as a means to assess circulating metabolites in early human clinical studies.
    Tiller PR; Yu S; Bateman KP; Castro-Perez J; McIntosh IS; Kuo Y; Baillie TA
    Rapid Commun Mass Spectrom; 2008 Nov; 22(22):3510-6. PubMed ID: 18853407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of solute carrier (SLC) drug uptake transporter loss in human and rat cryopreserved hepatocytes on clearance predictions.
    Lundquist P; Lööf J; Sohlenius-Sternbeck AK; Floby E; Johansson J; Bylund J; Hoogstraate J; Afzelius L; Andersson TB
    Drug Metab Dispos; 2014 Mar; 42(3):469-80. PubMed ID: 24396146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro evaluation of major in vivo drug metabolic pathways using primary human hepatocytes and HepaRG cells in suspension and a dynamic three-dimensional bioreactor system.
    Darnell M; Ulvestad M; Ellis E; Weidolf L; Andersson TB
    J Pharmacol Exp Ther; 2012 Oct; 343(1):134-44. PubMed ID: 22776955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how?
    Penner N; Xu L; Prakash C
    Chem Res Toxicol; 2012 Mar; 25(3):513-31. PubMed ID: 22309195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites.
    Wang WW; Khetani SR; Krzyzewski S; Duignan DB; Obach RS
    Drug Metab Dispos; 2010 Oct; 38(10):1900-5. PubMed ID: 20595376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.
    Wong H; Chen JZ; Chou B; Halladay JS; Kenny JR; La H; Marsters JC; Plise E; Rudewicz PJ; Robarge K; Shin Y; Wong S; Zhang C; Khojasteh SC
    Xenobiotica; 2009 Nov; 39(11):850-61. PubMed ID: 19845436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism of propafenone and verapamil by cryopreserved human, rat, mouse and dog hepatocytes: comparison with metabolism in vivo.
    Reder-Hilz B; Ullrich M; Ringel M; Hewitt N; Utesch D; Oesch F; Hengstler JG
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Apr; 369(4):408-17. PubMed ID: 14999438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Software-aided structural elucidation in drug discovery.
    Ahlqvist M; Leandersson C; Hayes MA; Zamora I; Thompson RA
    Rapid Commun Mass Spectrom; 2015 Nov; 29(21):2083-9. PubMed ID: 26443410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
    Zhang D; Wang L; Raghavan N; Zhang H; Li W; Cheng PT; Yao M; Zhang L; Zhu M; Bonacorsi S; Yeola S; Mitroka J; Hariharan N; Hosagrahara V; Chandrasena G; Shyu WC; Humphreys WG
    Drug Metab Dispos; 2007 Jan; 35(1):150-67. PubMed ID: 17062777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy.
    Obach RS
    Pharmacol Rev; 2013 Apr; 65(2):578-640. PubMed ID: 23406671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.